** Brokerage H.C. Wainwright starts coverage on cancer therapy maker ImmunityBio IBRX.O with "buy" rating and $8 PT; represents 161% upside to the stock's last close
** Brokerage says co is expected to see "compelling growth opportunity for 2025" in its bladder cancer therapy, Anktiva; estimates $4.3 bln in sales by 2034
** Believes Anktiva can be a "backbone therapy" with a wide range of applications, but its value is "highly underappreciated"
** Anktiva + BCG vaccine achieved the highest complete response rate, 62%, outperforming competitors like Merck's MRK.N Keytruda and Ferring's Adstiladrin - Brokerage
** Last month, FDA authorized co's new version of the BCG vaccine to treat bladder clancer
** IBRX fell ~51% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。